本帖最后由 老马 于 2012-1-13 21:20 编辑 " l4 p: x+ F6 N- @! ~/ H
3 d6 j- w; F' ^5 D8 s爱必妥和阿瓦斯丁的比较: K5 C% I1 h7 }& y6 c, M4 ?) {
1 C9 m; i* R& b3 ^http://cancergrace.org/lung/2008/08/30/bms099-os-neg/+ E- o! e8 g; c6 U+ @
8 x0 h& {$ L3 J: |
" j7 t; H% X% A- K$ ^ E9 Vhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
1 [; H; `' S7 N9 w==================================================0 d- \. p! u' E# o9 e1 A& r
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
! `: R* R9 ?! Z$ B4 ?9 ]0 I# zPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
5 V' R/ {5 `, l# x- u) U" }9 L x/ pResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.3 V/ Z: g; K6 j% ^- B
|